Abstract

The present invention relates to a method of purifying botulinum toxin, comprising the steps of: purifying the toxin by using multimode chromatography; and purifying the toxin by using cation exchange chromatography. When the botulinum toxin is purified and prepared by the purification method according to the present invention, botulinum toxin of a high purity of 99% or more can be purified in a high yield, and thus the present invention is useful for the production of botulinum toxin.

IPC Classes  ?

• C12N 9/52 - Proteinases derived from bacteria
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 1/18 - Ion-exchange chromatography

Goods & Services

Pharmaceutical preparations for health care; nutritional supplements for animal foodstuffs; animal repellents; vitamins for animals; dietary supplements for animals; veterinary preparations; antibiotic food supplements for animals; pharmaceutical products for skin care for animals; preparations of trace elements for human and animal use; lotions for veterinary purposes; disinfectants for veterinary use; dietetic food adapted for veterinary use; veterinary preparations and substances; probiotic bacterial formulations for veterinary use; diapers for pets; medicated animal feed; dietetic animal foodstuffs for medical purposes; adhesive patches for medical purposes; ethical medicinal preparations; nutraceutical preparations for therapeutic or medical purposes. Flavorings for animal feed; livestock fattening preparations; animal foodstuffs; yeast for animal consumption; live fish [not for food]; fodder; live insects; live animals; algae, unprocessed, for human or animal consumption; fresh fruits and vegetables; sand for pet toilets; snacks for pets; litter for domestic animals; chewing gum for pets; pet food; powdered milk for pets; beverages for pets; pet treats, edible; pet birds.

Goods & Services

Flavorings for animal feed, namely, foodstuff for animals containing botanical extracts; animal fattening preparations for livestock, namely, mash for fattening animals; animal foodstuffs; yeast for animal consumption; fodder; live insects; live animals; algae, unprocessed, for human or animal consumption; fresh fruits and vegetables; sand for pet toilets, namely, sand being litter for pets for pet toilets; snacks for pets, namely, pet food used as pet snacks; litter for domestic animals; chewing gum for pets; pet food; powdered milk for pets; beverages for pets; pet treats, edible; live pet birds Pharmaceutical preparations for health care, namely, pharmaceutical preparations for treatment of endocrine system disorders; nutritional supplements for animal foodstuffs; animal repellents; vitamins for animals; dietary supplements for animals; veterinary preparations, namely, amino acid preparations for veterinary use and bacterial preparations for veterinary use; antibiotic food supplements for animals; pharmaceutical products for skin care for animals; preparations of trace elements for human and animal use, namely, vitamin preparations; lotions, namely, medicated lotions, for veterinary purposes; disinfectants for veterinary use; dietetic food adapted for veterinary use; veterinary preparations and substances, namely, diagnostic preparations for veterinary use; probiotic bacterial formulations for veterinary use, namely, nutritional supplements in the nature of probiotic compositions for veterinary use; diapers for pets; medicated animal feed; dietetic animal foodstuffs for medical purposes; adhesive patches for medical purposes, namely, preparations in the form of adhesive patches for repelling helminths for medical purposes; ethical medicinal preparations, namely, pharmaceutical preparations for treatment of atopic dermatitis disorders; nutraceutical preparations for therapeutic or medical purposes, namely, for use as a dietary supplement for liver support

Abstract

The present invention relates to a botulinum toxin freeze-dried dosage form composition storable for a long time, comprising botulinum toxin, protamine sulfate, an isotonic agent and a buffer agent, and a botulinum toxin freeze-dried dosage form according to the present invention lowers the inactivation rate of botulinum toxin during freeze-drying, can maintain the stability of botulinum toxin for longer than a conventional botulinum toxin freeze-dried dosage form, forms a uniform particle size so that the effect exhibited at the site of administration is the same and can prevent the side effect in which an excessive toxin administration effect is exhibited only at some sites.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein

Goods & Services

Cardiovascular pharmaceutical preparations; Diagnostic preparations for medical or veterinary purposes; Dietary supplements for animals; Dietary supplements for pets; Dietary supplements for human beings; Liquid vitamin supplements; Mineral food supplements; Mineral supplements; Mixed vitamin preparations; Multivitamin preparations; Nutritional supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for animal skincare; Pharmaceutical products for skin care for animals; Vitamin fortified beverages for medical purposes; Vitamin preparations; Vitamins for animals; Vitamins for pets

Goods & Services

Pharmaceutical preparations for health care, namely, pharmaceutical preparations for treatment of endocrine system disorders; nutritional supplements for animal foodstuffs; animal repellents; vitamins for animals; dietary supplements for animals; pharmaceutical preparations for animals, namely, cholagogues; antibiotic food supplements for animals; pharmaceutical products for skin care for animals; preparations of trace elements for human and animal use, namely, vitamin preparations; lotions, namely, medicated lotions, for veterinary purposes; disinfectants for veterinary use; dietetic food adapted for veterinary use; veterinary preparations and substances, namely, diagnostic preparations for veterinary use; probiotic bacterial formulations for veterinary use; diapers for pets; medicated animal feed; dietetic animal foodstuffs for medical purposes; adhesive patches for medical purposes, namely, preparations in the form of adhesive patches for repelling helminths for medical purposes; ethical medicinal preparations, namely, pharmaceutical preparations for treatment of atopic dermatitis disorders; nutraceutical preparations for therapeutic or medical purposes, namely, for use as a dietary supplement for liver support Flavorings for animal feed, namely, foodstuff for animals containing botanical extracts; animal fattening preparations, namely, mash for fattening animals; animal foodstuffs; yeast for animal consumption; live fish; animal feed; live insects; live animals; seaweed, unprocessed, for human or animal consumption; fresh fruits and vegetables; sand for pet toilets; snacks for pets; litter for domestic animals; chewing gum for pets; pet food; powdered milk for pets; beverages for pets; pet treats, namely, edible pet treats; pet treats, edible; live pet birds

Goods & Services

Pharmaceutical preparations for health care; nutritional supplements for animal foodstuffs; animal repellents; vitamins for animals; dietary supplements for animals; veterinary preparations; antibiotic food supplements for animals; pharmaceutical products for skin care for animals; preparations of trace elements for human and animal use; lotions for veterinary purposes; disinfectants for veterinary use; dietetic food adapted for veterinary use; veterinary preparations and substances; probiotic bacterial formulations for veterinary use; diapers for pets; medicated animal feed; dietetic animal foodstuffs for medical purposes; adhesive patches for medical purposes; ethical medicinal preparations; nutraceutical preparations for therapeutic or medical purposes. Flavorings for animal feed; livestock fattening preparations; animal foodstuffs; yeast for animal consumption; live fish [not for food]; fodder; live insects; live animals; algae, unprocessed, for human or animal consumption; fresh fruits and vegetables; sand for pet toilets; snacks for pets; litter for domestic animals; chewing gum for pets; pet food; powdered milk for pets; beverages for pets; pet treats, edible; pet birds.

Goods & Services

Protein dietary supplements; mineral food supplements; dietary supplements with a cosmetic effect; dietary fiber; plant extracts for pharmaceutical purposes; cachets for pharmaceutical purposes; chemico-pharmaceutical preparations; nutritional supplements; lyophilized food adapted for medical purposes; adjuvants for medical purposes; dietetic substances adapted for medical use; medicinal drinks; pharmaceuticals; lutein dietary supplements; royal jelly dietary supplements; dietary supplements consisting of trace elements; dietary supplements consisting of amino acids; zinc dietary supplements; dietary supplements for humans; calcium supplements; glucose dietary supplements; vitamin preparations; milk sugar for pharmaceutical purposes; food for babies; drugs for medical purposes; nutraceutical preparations for therapeutic or medical purposes; pharmaceutical preparations for health care; nutraceutical preparations mainly based on egg; nutraceuticals for use as a dietary supplement; health food supplements made principally of minerals; health food supplements made principally of vitamins; probiotic supplements.

Goods & Services

Protein dietary supplements; mineral food supplements; dietary supplements with a cosmetic effect; dietary fiber; plant extracts for pharmaceutical purposes; cachets for pharmaceutical purposes; chemico-pharmaceutical preparations; nutritional supplements; lyophilized food adapted for medical purposes; adjuvants for medical purposes; dietetic substances adapted for medical use; medicinal drinks; pharmaceuticals; lutein dietary supplements; royal jelly dietary supplements; dietary supplements consisting of trace elements; dietary supplements consisting of amino acids; zinc dietary supplements; dietary supplements for humans; calcium supplements; glucose dietary supplements; vitamin preparations; milk sugar for pharmaceutical purposes; food for babies; drugs for medical purposes; nutraceutical preparations for therapeutic or medical purposes; pharmaceutical preparations for health care; nutraceutical preparations mainly based on egg; nutraceuticals for use as a dietary supplement; health food supplements made principally of minerals; health food supplements made principally of vitamins; probiotic supplements.

Abstract

The present invention relates to a botulinum toxin freeze-dried dosage form composition storable for a long time, comprising botulinum toxin, protamine sulfate, an isotonic agent and a buffer agent, and a botulinum toxin freeze-dried dosage form according to the present invention lowers the inactivation rate of botulinum toxin during freeze-drying, can maintain the stability of botulinum toxin for longer than a conventional botulinum toxin freeze-dried dosage form, forms a uniform particle size so that the effect exhibited at an administration is the same and can prevent the side effect in which an excessive toxin administration effect is exhibited only at some sites.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

The present invention relates to a botulinum toxin freeze-dried dosage form composition storable for a long time, comprising botulinum toxin, protamine sulfate, an isotonic agent and a buffer agent, and a botulinum toxin freeze-dried dosage form according to the present invention lowers the inactivation rate of botulinum toxin during freeze-drying, can maintain the stability of botulinum toxin for longer than a conventional botulinum toxin freeze-dried dosage form, forms a uniform particle size so that the effect exhibited at an administration is the same and can prevent the side effect in which an excessive toxin administration effect is exhibited only at some sites.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)

Abstract

The present invention relates to a pharmaceutical composition for intramuscular and/or subcutaneous administration of niclosamide, containing niclosamide or a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, the composition exhibiting the effect of maintaining a high blood concentration for a long time, and being effectively usable in the prevention or treatment of virus-related diseases.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/10 - DispersionsEmulsions
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a cell therapy product comprising embryonic stem cell-derived mesenchymal stem cells as an active ingredient for treatment of stroke. According to the present invention, administration of embryonic stem cell-derived mesenchymal stem cells and EPO in combination to a stroke patient can be expected to bring about recovery from cranial nerve injury and effective alleviation in stroke-induced conductor disorder.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Goods & Services

All purpose deodorizing preparations for household, commercial or industrial use; veterinary preparations; insect repellants; mothproofing paper; food supplements; pharmaceuticals containing botulinum toxin; vitamin and mineral food supplements; fungicides; wound dressings; bacterial poisons; breast-nursing pads; dietary supplements; eye bandages; milk sugar for pharmaceutical purposes; powdered milk foods for infants; food for babies; bone cement for surgical and orthopedic purposes; surgical implants (living tissues); dietary supplements for infants; medicated plasters; bacterial preparations for medical purposes; adhesive compositions for medical use; medicines for human purposes; disposable diapers; embedding material for dental and dental technical purposes; glue coated strips for use against vermin; portable first-aid kits.

Goods & Services

(1) All purpose deodorizing preparations for household, commercial and industrial use; deodorizing preparations for use on non-porous surfaces in veterinary and pet care facilities; air fresheners being air deodorizing preparations; veterinary vaccines; veterinary pharmaceutical preparations for treatment of intestinal bacteria in mammals; insect repellants; mothproofing paper; vitamin and mineral food supplements; pet food additives in the form of vitamins and minerals; Herbal food supplements for health and well-being; Hemp-based food supplements; pharmaceuticals preparations being botulinum toxin; vitamin and mineral food supplements; fungicides; wound dressings; bacterial poisons; breast-nursing pads; dietary supplements for general health and well-being; dietary supplements for building body mass; dietary supplements consisting of herbs, vegetables, fruits, grains and fish oil in capsule, liquid and powder form to improve general health; dietary supplements used for weight loss; dietary supplements consisting of vitamins and minerals; dietary supplements for pets for general health and well-being; eye bandages; lactose for pharmaceutical purposes; powdered milk foods for infants; food for babies; bone cement for surgical and orthopedic purposes; surgical implants (living tissues); medicated plasters; probiotic bacterial formulations for medical purposes; adhesive plasters for medical purposes; medical adhesives for binding wounds; medical adhesives for binding internal tissue; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of hyperlipidemia; preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of Musculo-skeletal disorders; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for treating halitosis; antiemetics; local anaesthetics; analgesics; muscle relaxants; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders, and neuromuscular diseases, namely primary periodic paralysis; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations and substances for use in treatment and diagnostics in the field of gynecology; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for preventing and treating obesity; pharmaceutical preparations for the treatment of rhinitis; anesthetics for non-surgical use; vitamin and mineral supplements; disposable diapers; embedding material for dental and dental technical purposes; preparations for destroying and combating vermin, namely, glue coated strips; portable first-aid kits.

Goods & Services

Adhesives for affixing false hair; de-greasing preparations for household purposes; polishing, scouring and abrasive preparations; polishing preparations; shining preparations being polish; shoe polish applicators containing shoe polish; deodorants for animals; pre-moistened cosmetic cleansing tissues; cleansers for intimate personal hygiene purposes, non-medicated; mouthwashes, not for medical purposes; Non-medicated toiletry preparations; Liquid laundry detergents; Liquid detergents for household use; Liquid dishwashing detergents; cleaning and polishing preparations; cleaning, polishing, scouring and abrasive preparations; cleaning preparations; Laundry detergents; Laundry soaps; laundry bleach; laundry starch; hand cleansers; food flavoring, being essential oils; room fragrancing preparations; essential oils; Non-medicated feminine hygiene wash; Feminine hygiene cleansing towelettes; Abrasive cleaning preparations; Skin abrasive preparations; Nasal cleaning preparations for personal sanitary purposes; Vaginal washes for personal sanitary or deodorant purposes; shampoos for human hair; deodorants for human beings or for animals; Non-medicated soaps for personal use; cleansing preparations for personal use; degreasers, other than for use in manufacturing processes; Pads, tissues or wipes pre-moistened or impregnated with non-medicated skin cleaning preparations; perfumes; pre-moistened cosmetic tissues; Baby wipes for cosmetic use impregnated with cleaning preparations; cosmetics

Goods & Services

Microneedle patches containing non-medicated skin care preparations; Non-medicated cosmetics, namely, non-medicated acne creams for the skin; cosmetic preparations for skin renewal; Patches containing non-medicated skin care preparations Adhesive patches containing medicated skin care preparations; Medical and surgical dressings; wet dressing material used in the treatment of wounds; Wet dressings for the treatment of acne; adhesive bandages for transdermal administering of pharmaceutical products, namely, adhesive bandages for the treatment of acne; adhesive bandages for transdermal administering of non-medicated products, namely, adhesive bandages for the treatment of acne; adhesive skin patches for the treatment of acne; medicated transdermal patches for use in the treatment of acne; non-medicated transdermal patches for use in the treatment of acne; topical ointments for the treatment of acne; medicated topical ointments for the treatment of acne; acne treatment preparations, namely, acne treatment ointments; topical gels and creams for the treatment of acne; medicated topical gels and creams for the treatment of acne; acne treatment preparations, namely, acne treatment creams and gels; acne treatment preparations; Microneedle patches containing acne treatment preparations

Abstract

A stable liquid composition comprising a botulinum toxin as an active ingredient is described, which is ready-to-use without the need for a reconstitution process, and thus, it is possible to improve user's convenience, and reduce a deviation of botulinum toxin activity due to dilution errors in the reconstitution process. Further, the liquid composition efficiently prevents the botulinum toxin from aggregating even at a low botulinum toxin concentration to thereby have extremely excellent storage stability, and efficiently prevents adsorption of the botulinum toxin to a container, thereby constantly maintaining an activity of the botulinum toxin for each batch or for each liquid vial.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Goods & Services

Dentifrices made of crude medicines; cleansers for detergent; liquid dentifrices; dental rinses for non-medical purposes; tooth powder; dentifrices; teeth whitening preparations; breath freshening strips; breath freshening sprays; pre-moistened tissues of paper for babies; pre-moistened tissues of paper for babies for the use of mouthwashes; pre-moistened tissues of paper for hygiene purposes; pre-moistened tissues; teeth whitening strips; tooth polishes; cosmetic preparations for the care of mouth and teeth; dentifrices for babies; anticavity mouth rinses, not for medical purposes; breath fresheners, not for medical purposes; non-medicated mouthwashes and gargles; tooth whitening pastes; dentifrice powder; dentifrice gels. Mouth sprays for medical use; medicated dentifrices; gargles for medical purposes; mouthwashes (gargles) for medical purposes; medicated dental rinses; anti-cavity mouth rinses for medical purposes; medicated anti-cavity mouthwashes; medicines for human purposes; preparations to facilitate teething; preparations for stimulating teeth growth; drugs for medical purposes; medicated mouth care and treatment preparations; mouthwashes for medical purposes; breath refreshers for medical purposes; breath-freshening chewing gum for medicinal purposes. Teething rings for babies; gum massaging instruments; gum massagers for babies; oral irrigators; medical teeth whitening apparatus; teething rings dummies (teats); teething rings; mouth wash apparatus for dental purposes; oral irrigators for use in dentistry; dental instruments; dental apparatus and instruments; dental apparatus; medical toothbrush sterilizer; dental teeth whitening apparatus with LED light; teeth protectors for dental purposes. Potable sterilizer for toothbrush; sterilizer for toothbrush. Power-operated toothbrushes; toothbrushes; toothbrush cases; dental floss dispensers; interdental cleaners; sprayers for cleaning gums and teeth; medicated dental floss; denture baths; toothbrushes for babies; manual toothbrushes; end-tufted toothbrushes; dental floss; teeth whitening trays [receptacles] for home use; electric toothbrushes; heads for electric toothbrushes; tongue cleaners; toothbrush holders; toothbrush bristles; interdental brushes for cleaning the teeth; water apparatus for cleaning teeth and gums; floss for dental purposes; dental tape.

Goods & Services

Cosmetic preparations for the care of mouth and teeth; breath freshening sprays; breath freshening strips; pre-moistened tissues; tooth whitening pastes; non-medicated mouthwashes and gargles; breath freshening preparations, not for medical purposes; dental rinses, not for medical purposes; anticavity mouth rinses, not for medical purposes; liquid dentifrices; pre-moistened tissues for personal hygiene; pre-moistened tissues of paper for babies' mouthwashes; pre-moistened tissues of paper for babies; dentifrices for babies; teeth polishing preparations; teeth whitening strips; teeth whitening preparations; dentifrices; dentifrice gels; dentifrice powder. Anticavity mouth rinses for medical purposes; medicated dentifrices; gargles for medical purposes; medicated mouth care and treatment preparations; mouthwashes for medical purposes; oral disinfectants for medical purposes; oral sprays for medical purposes; mouthwashes [gargles] for medical purposes; breath freshening preparations for medical purposes; drugs for medical purposes; dental rinses for medical purposes; anticavity mouthwashes for medical purposes; medicines for human purposes; preparations to facilitate teething; preparations for stimulating teeth growth. Tongue cleaners. Teeth whitening trays [receptacles] for home use; dental floss; end-tufted toothbrushes; manual toothbrushes; toothbrushes for babies; dental floss for medical purposes; denture baths; sprayers for cleaning gums and teeth; interdental cleaners; dental floss dispensers; dental tape; floss for dental purposes; water apparatus for cleaning teeth and gums; interdental brushes for cleaning the teeth; toothbrushes; toothbrush cases; toothbrush bristles; toothbrush holders.

Goods & Services

Botulinum toxin for medical use. Biotechnological research; development of pharmaceutical preparations.

Goods & Services

(1) Pharmaceutical products, namely botulinum toxin for use in the field of aesthetic, beauty and medicine; injectable botulinum toxin for medical use for use in aesthetic procedures, namely the treatment of wrinkles; and botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction. (1) Research and development services in the field of biotechnology development of pharmaceutical preparations.

Goods & Services

Botulinum toxin for medical use Biotechnological research in the field of pharmaceutical preparations; development of pharmaceutical preparations; none of the above including or related to isolation and purification of nucleic acids

Abstract

The present invention relates to a method for producing a botulinum toxin comprising: (a) treating a culture of a botulinum toxin-producing strain with acid to form a botulinum toxin-containing precipitate; (b) adding a buffer to the botulinum toxin-containing precipitate of step (a), followed by clarification by at least one method selected from the group consisting of depth filtration (DF), microfiltration (MF), ultrafiltration (UF), sterile filtration, membrane chromatography (MC) and centrifugation; (c) subjecting the botulinum toxin-containing solution of step (b) to UF diafiltration, ammonium sulfate precipitation or hydrochloric acid precipitation, and then diluting a retentate resulting from the UF diafiltration in a buffer or dissolving a precipitate resulting from the ammonium sulfate precipitation or hydrochloric acid precipitate in a buffer; and (d) subjecting the retentate dilution, ammonium sulfate precipitate solution or hydrochloric acid precipitate solution of step (c) to anion-exchange chromatography (AEX) to purify the botulinum toxin.

IPC Classes  ?

• C12N 9/52 - Proteinases derived from bacteria
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• B01D 61/14 - UltrafiltrationMicrofiltration
• B01D 61/58 - Multistep processes
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)

Abstract

The present disclosure relates to a stable liquid composition comprising a botulinum toxin as an active ingredient which is ready-to-use without the need for a reconstitution process, and particularly, to a liquid composition capable of preventing the botulinum toxin from aggregating even when the botulinum toxin is contained at a low concentration to thereby exhibit high stability, and efficiently preventing adsorption, etc., to a container, to constantly maintain an activity of the botulinum toxin for each batch or for each liquid vial. Specifically, the present disclosure relates to the liquid composition comprising (i) a botulinum toxin as an active ingredient, (ii) L-alanine or methyl cellulose, (iii) a non-ionic surfactant, and (iv) a buffer, and optionally, an isotonic agent. The liquid composition of the botulinum toxin according to the present disclosure is which is ready-to-use without performing a reconstitution process, and thus, it is possible to improve user's convenience, and reduce a deviation of botulinum toxin activity, etc., due to dilution errors in the reconstitution process, etc. Further, the liquid composition according to the present disclosure efficiently prevents the botulinum toxin from aggregating even at a low botulinum toxin concentration to thereby have extremely excellent storage stability, and efficiently prevents adsorption of the botulinum toxin to a container, thereby constantly maintaining an activity of the botulinum toxin for each batch or for each liquid vial.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof

Abstract

The present disclosure relates to a stable liquid composition comprising a botulinum toxin as an active ingredient which is ready-to-use without the need for a reconstitution process, and particularly, to a liquid composition capable of preventing the botulinum toxin from aggregating even when the botulinum toxin is contained at a low concentration to thereby exhibit high stability, and efficiently preventing adsorption, etc., to a container, to constantly maintain an activity of the botulinum toxin for each batch or for each liquid vial. Specifically, the present disclosure relates to the liquid composition comprising (i) a botulinum toxin as an active ingredient, (ii) L-alanine or methyl cellulose, (iii) a non-ionic surfactant, and (iv) a buffer, and optionally, an isotonic agent. The liquid composition of the botulinum toxin according to the present disclosure is which is ready-to-use without performing a reconstitution process, and thus, it is possible to improve user's convenience, and reduce a deviation of botulinum toxin activity, etc., due to dilution errors in the reconstitution process, etc. Further, the liquid composition according to the present disclosure efficiently prevents the botulinum toxin from aggregating even at a low botulinum toxin concentration to thereby have extremely excellent storage stability, and efficiently prevents adsorption of the botulinum toxin to a container, thereby constantly maintaining an activity of the botulinum toxin for each batch or for each liquid vial.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

Clostridium botulinum, the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/52 - Proteinases derived from bacteria
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/52 - Proteinases derived from bacteria
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)

Abstract

Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Clostridium botulinum, the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/52 - Proteinases derived from bacteria

Abstract

The present invention relates to a method for producing a botulinum toxin comprising :(a) treating a culture of a botulinum toxin-producing strain with acid to form a botulinum toxin-containing precipitate; (b) adding a buffer to the botulinum toxin-containing precipitate of step (a), followed by clarification by at least one method selected from the group consisting of depth filtration (DF), microfiltration (MF), ultrafiltration (UF), sterile filtration, membrane chromatography (MC) and centrifugation; (c) subjecting the botulinum toxin-containing solution of step (b) to UF diafiltration, ammonium sulfate precipitation or hydrochloric acid precipitation, and then diluting a retentate resulting from the UF diafiltration in a buffer or dissolving a precipitate resulting from the ammonium sulfate precipitation or hydrochloric acid precipitate in a buffer; and (d) subjecting the retentate dilution, ammonium sulfate precipitate solution or hydrochloric acid precipitate solution of step (c) to anion-exchange chromatography (AEX) to purify the botulinum toxin.

IPC Classes  ?

• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 1/18 - Ion-exchange chromatography
• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion

Abstract

The present invention relates to a method for producing a botulinum toxin comprising :(a) treating a culture of a botulinum toxin-producing strain with acid to form a botulinum toxin-containing precipitate; (b) adding a buffer to the botulinum toxin-containing precipitate of step (a), followed by clarification by at least one method selected from the group consisting of depth filtration (DF), microfiltration (MF), ultrafiltration (UF), sterile filtration, membrane chromatography (MC) and centrifugation; (c) subjecting the botulinum toxin-containing solution of step (b) to UF diafiltration, ammonium sulfate precipitation or hydrochloric acid precipitation, and then diluting a retentate resulting from the UF diafiltration in a buffer or dissolving a precipitate resulting from the ammonium sulfate precipitation or hydrochloric acid precipitate in a buffer; and (d) subjecting the retentate dilution, ammonium sulfate precipitate solution or hydrochloric acid precipitate solution of step (c) to anion-exchange chromatography (AEX) to purify the botulinum toxin.

IPC Classes  ?

• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 1/18 - Ion-exchange chromatography
• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)

Goods & Services

[ Wholesale and retail store services featuring pharmaceutical and veterinary preparations; wholesale and retail store services featuring dietary supplements; wholesale and retail store services featuring cosmetics; procurement services for others purchasing pharmaceuticals for human and veterinary purposes ] [ Pharmaceutical preparations, namely, acetaminophen, acne medications, ] acne treatment preparations [ , adrenal hormone preparations, alcohol for topical use, allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, fungicides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretic preparations, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations, drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, adjuvants for use with vaccines, diuretics, amino acids for medical purposes; dietary and nutritional supplements; medicated skin lotions ] ; bandages for skin wounds; [ vitamin and mineral preparations for medical use; biological preparations for medical purposes for use in the treatment of the central nervous system, diabetes, skin disorders, wounds, eye diseases and conditions, swelling in the legs, respiratory diseases, asthma, erectile dysfunction, cardiovascular conditions, heart rhythm disorders and infectious diseases; all-purpose disinfecting preparations; pharmaceutical preparations for use in cardiovascular treatment; diagnostic preparations for medical purposes; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical agents affecting digestive organs; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; ] pharmaceutical preparations for treating wounds; [ pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations to prevent swelling in the legs; pharmaceutical preparations for treating respiratory diseases and asthma; pharmaceutical preparations for the treatment of erectile dysfunction; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; plant extracts for pharmaceutical purposes adapted for use in the treatment of the central nervous system, diabetes, skin disorders, wounds, eye diseases and conditions, swelling in the legs, respiratory diseases, asthma, erectile dysfunction, cardiovascular conditions, heart rhythm disorders and infectious diseases; plant extracts for pharmaceutical purposes adapted for use in chemotherapy; veterinary preparations for treatment of intestinal bacteria in mammals; veterinary vaccines; sanitary preparations for medical use; ] medical dressings

Goods & Services

[ Advertising services; publicity agency services; import-export agency services; sales promotion for others in the field of pharmaceuticals; providing business information in the field of pharmaceuticals; business management assistance in the field of pharmaceuticals; market research; conducting marketing studies; procuring of contracts for the purchase and sale of pharmaceuticals; wholesale and retail store services featuring pharmaceutical and veterinary preparations; wholesale and retail store services featuring dietary supplements; wholesale and retail store services featuring cosmetics; procurement services for others purchasing pharmaceuticals for human and veterinary purposes ] [ Pharmaceutical preparations, namely, acetaminophen, acne medications, ] acne treatment preparations ; [ , adrenal hormone preparations, alcohol for topical use, allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, fungicides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretic preparations, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations, drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, adjuvants for use with vaccines, diuretics, amino acids for medical purposes; dietary and nutritional supplements; medicated skin lotions; ] bandages for skin wounds; [ vitamin and mineral preparations for medical use; biological preparations for medical purposes for use in the treatment of the central nervous system, diabetes, skin disorders, wounds, eye diseases and conditions, swelling in the legs, respiratory diseases, asthma, erectile dysfunction, cardiovascular conditions, heart rhythm disorders and infectious diseases; all-purpose disinfecting preparations; pharmaceutical preparations for use in cardiovascular treatment; diagnostic preparations for medical purposes; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical agents affecting digestive organs; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; ] pharmaceutical preparations for treating wounds; [ pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations to prevent swelling in the legs; pharmaceutical preparations for treating respiratory diseases and asthma; pharmaceutical preparations for the treatment of erectile dysfunction; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; plant extracts for pharmaceutical purposes adapted for use in the treatment of the central nervous system, diabetes, skin disorders, wounds, eye diseases and conditions, swelling in the legs, respiratory diseases, asthma, erectile dysfunction, cardiovascular conditions, heart rhythm disorders and infectious diseases; plant extracts for pharmaceutical purposes adapted for use in chemotherapy; veterinary preparations for treatment of intestinal bacteria in mammals; veterinary vaccines; sanitary preparations for medical use; ] medical dressings

Abstract

The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• C12R 1/145 - Clostridium

Abstract

The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises a porcine peptone and at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones, porcine peptones and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)

Abstract

The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises a casein hydrolysate and at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones, casein hydrolysates and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.

IPC Classes  ?

• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/52 - Proteinases derived from bacteria
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises a casein hydrolysate and at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones, casein hydrolysates and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)

Abstract

The present invention provides a pharmaceutical composition in a powder form for providing wound protection, hemostasis, or anti-adhesion in the gastrointestinal tract, which comprises a certain mucoadhesive polymer; and a certain hygroscopic agent.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 9/14 - Particulate form, e.g. powders
• A61K 33/14 - Alkali metal chloridesAlkaline earth metal chlorides
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61L 31/04 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials

Abstract

A method of making botulinum toxin comprises treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and purifying the botulinum toxin by anion exchange chromatography. The use of the method makes it possible to produce a high-purity botulinum toxin by a simple process. The botulinum toxin produced by the method has high purity, and thus has an increased ability to act in a local area. Thus, the systemic circulation of the botulinum toxin is reduced to increase the safety. Accordingly, the botulinum toxin can be used for treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy.

IPC Classes  ?

• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• C12N 9/52 - Proteinases derived from bacteria

Abstract

The present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt as an active ingredient. And also, the present invention provides a cosmetic composition for improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt; and a food (i.e., a functional food) for preventing or improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt.

IPC Classes  ?

• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61Q 19/00 - Preparations for care of the skin
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

The present invention relates to a method for production of a botulinum toxin, and more particularly to a method for preparation of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. The use of the method of the invention toxin makes it possible to produce a high-purity botulinum toxin by a simple process, suggesting that the method is very economical and efficient. The botulinum toxin produced by the method of the invention has high purity compared to botulinum toxins produced by conventional methods, and thus has an increased ability to act in a local area. Thus, the systemic circulation of the botulinum toxin, which can result in side effects, is reduced to increase the safety. Accordingly, the botulinum toxin of the invention can be used for various purposes, including treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy.

IPC Classes  ?

• C07K 1/18 - Ion-exchange chromatography
• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types

Abstract

The present invention relates to a method for production of a botulinum toxin, and more particularly to a method for preparation of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. The use of the method of the invention toxin makes it possible to produce a high-purity botulinum toxin by a simple process, suggesting that the method is very economical and efficient. The botulinum toxin produced by the method of the invention has high purity compared to botulinum toxins produced by conventional methods, and thus has an increased ability to act in a local area. Thus, the systemic circulation of the botulinum toxin, which can result in side effects, is reduced to increase the safety. Accordingly, the botulinum toxin of the invention can be used for various purposes, including treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy.

IPC Classes  ?

• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C07K 1/18 - Ion-exchange chromatography

Abstract

The present invention relates to a complex formulation containing metformin used in the treatment of non-insulin dependent diabetes and an HMG-CoA reductase inhibitor used in the treatment of dyslipidemia. The present invention provides a complex formulation and a method for preparing the complex formulation, wherein the complex formulation contains metformin and an HMG-CoA reductase inhibitor, and has effectively improved stability by securing the stable release of respective active ingredients and blocking physical and chemical reactions between the active ingredients.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/22 - Sustained or differential release type
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)

Abstract

The present invention provides a pharmaceutical composition in a powder form for providing wound protection, hemostasis, or anti-adhesion in the gastrointestinal tract, which comprises a certain mucoadhesive polymer; and a certain hygroscopic agent.

IPC Classes  ?

• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61K 38/18 - Growth factorsGrowth regulators

Abstract

Provided is a composition for preventing or treating atopic dermatitis, comprising 2-amino-1,9-dimethyl purine-6-one or a pharmaceutically acceptable salt thereof as an active ingredient. Further provided is a cosmetic composition comprising 2-amino-1,9-dimethyl purine-6-one or a pharmaceutically acceptable salt thereof for improving atopic dermatitis. Also provided is a food (i.e. a functional food) comprising 2-amino-1,9-dimethyl purine-6-one or a pharmaceutically acceptable salt thereof for preventing or improving atopic dermatitis.

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present invention relates to an inner tub support structure for an LNG storage tank for a ship, and more particularly, to an inner tub support structure for an LNG storage tank for a ship, in which extension/contraction in a circumferential direction and lengthwise direction of the inner tub is not limited during an extension/contraction of the inner tub resulting from a temperature variation caused by a storage and discharge of LNG. To this end, an inner tub support structure for an LNG storage tank for supporting an inner tub of the LNG storage tank having a cylindrical outer tub and a cylindrical inner tub, comprises a sliding main supporter which is arranged in one side of a bottom of the outer tub so as to fix the center of a bottom surface of the inner tub, and which has an elongated sliding groove formed in the lengthwise direction of the inner tub; a fixing main supporter which is arranged in the other side of the bottom of the outer tub so as to fix the center of the bottom surface of the inner tub, and which has a circular groove; and a sub supporter which is arranged in the bottom of the outer tub so as to support the bottom surface of the inner tub, wherein the bottom surface of the inner tub is not fixed at the sub supporter.

IPC Classes  ?

• F17C 13/08 - Mounting arrangements for vessels
• B65D 90/12 - Supports

Abstract

Provided is a pharmaceutical composition for preventing or treating mucus hypersecretion in airways or chronic obstructive pulmonary diseases (COPDs), the pharmaceutical composition including an epidermal growth factor (EGF) and a pharmaceutically acceptable carrier.　 In addition, a combined preparation capable of respectively administering the pharmaceutical composition and chemotherapeutics is provided.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators

Abstract

The present invention relates to a topically applicable composition for preventing or treating alopecia caused by a chemotherapeutic agent, including a nanoliposome consisting of a liposome layer containing a lecithin, wherein the nanoliposome includes an epidermal growth factor. In addition, the present invention relates to a pharmaceutical combination which contains the above-described composition and chemotherapeutic agent such that the composition and the chemotherapeutic agent can be individually administered.

IPC Classes  ?

• A61K 8/14 - Liposomes

Abstract

Provided is a liquid composition for treating stomatitis, the liquid composition including: an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and dextran. The liquid composition includes a stabilizer selected from EDTA (or salts thereof) and a certain amino acid (or inorganic acid salts thereof) and thus, physicochemical and biological stability of the epidermal growth factor can be substantially increased. Thus, the liquid composition can be stored and distributed for a long period of time. The stabilized composition includes an adhesive polymer, and thus, when ejected in a spray form in the mouth of a user, the liquid composition can be quickly attached to an inflammation site and exhibits effectiveness for a long period of time.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers

Abstract

Disclosed herein is a stable liquid formulation comprising human growth hormone; L-lysine, L-arginine or polyethylene glycol 300; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethylene glycol-15 polyoxystearate or polyethylene glycol-35 castor oil.

IPC Classes  ?

• A61K 38/27 - Growth hormone [GH], i.e. somatotropin
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein

Abstract

The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according to the present invention has long-term stability and uniformity, and so can be used to prepare a composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like. In particular, the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereby showing an excellent effect of stimulating skin-penetration and good pharmaceutical stability. Also, the esterified lecithin used in preparing liposome can provide effects of softening skin and stimulating skin-penetration, thereby enhancing the penetration of epidermal growth factor and natural extract into skin, as well as additional moisturizing effect which is advantageous in treating skin diseases. Further, since the present composition comprises nanoliposome prepared by containing esterified lecithin in liposome membrane, the conventional problems of heating and dispersing active ingredients at high temperature (70° C. or more), low stability and uniformity, or the like can be solved.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 8/14 - Liposomes
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus

Abstract

Provided is a stable HSA-free and antioxidant-free pharmaceutical composition including: interferon-beta; a buffer with a pH between 3 and 5 including lactic acid or L-histidine; a polyoxyethylene-polyoxypropylene copolymer or polyvinylpyrrolidone; and an isotonic agent. The stable HSA-free pharmaceutical composition prevents the formation of deaminated products or aggregates caused by physical and/or chemical stress, maintains biological activity, and significantly blocks the formation of impurities such as deaminated products, aggregates and oxides of interferon-beta without using an antioxidant such as ethylene-diamine-tetra-acetic acid (EDTA), methionine, or the like.

IPC Classes  ?

• A61K 38/21 - Interferons

Abstract

Provided is a liquid composition for treating stomatitis, the liquid composition including: an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and dextran. The liquid composition includes a stabilizer selected from EDTA (or salts thereof) and a certain amino acid (or inorganic acid salts thereof) and thus, physicochemical and biological stability of the epidermal growth factor can be substantially increased. Thus, the liquid composition can be stored and distributed for a long period of time. The stabilized composition includes an adhesive polymer, and thus, when ejected in a spray form in the mouth of a user, the liquid composition can be quickly attached to an inflammation site and exhibits effectiveness for a long period of time.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 38/18 - Growth factorsGrowth regulators

Abstract

The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according to the present invention has long-term stability and uniformity, and so can be used to prepare a composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like. In particular, the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereby showing an excellent effect of stimulating skin-penetration and good pharmaceutical stability. Also, the esterified lecithin used in preparing liposome can provide effects of softening skin and stimulating skin-penetration, thereby enhancing the penetration of epidermal growth factor and natural extract into skin, as well as additional moisturizing effect which is advantageous in treating skin diseases. Further, since the present composition comprises nanoliposome prepared by containing esterified lecithin in liposome membrane, the conventional problems of heating and dispersing active ingredients at high temperature (70 °C or more), low stability and uniformity, or the like can be solved.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

Disclosed herein is a stable liquid formulation comprising human growth hormone; L-lysine, L-arginine or polyethylene glycol 300; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethylene glycol- 15 polyoxystearate or polyethylene glycol-35 castor oil.

IPC Classes  ?

• A61K 38/27 - Growth hormone [GH], i.e. somatotropin
• A61K 9/08 - Solutions
• A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

The present invention relates to a container assembly having a structure capableof upplying new liquid contents held in a second container to a first container without separating the members, to solve the above problems occurring in a container having a structure mixing two contents. The container assembly according to one embodiment of the present invention comprises a first container holding first contents; a rotating member disposed under the first container at a rotatable state; a guiding member disposed in the rotating member in a fixed state and including an upper guide and a lower guide having regular interval; a second container disposed in the guiding member; including a connecting member that penetrates an upper guide of the guiding member and is connected to the rotating member; thereby rising and rotating along the upper guide of the guiding member by rotation of the rotating member; and having an injecting member in its upper end; and a piston member disposed under the second container in the guiding member; including the connecting member that penetrates a lower guide of the guiding member and is connected to the rotating member; and so pressing the second container by rising and rotating along the lower guide of the guiding member by rotation of the rotating member.

IPC Classes  ?

• B65D 81/32 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Abstract

Disclosed is a composition for treating cancer including oligodeoxynucleotides and LPS-derived non-toxic lipopolysaccharides as effective components.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/739 - Lipopolysaccharides
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a sustained release film formulation for healing wound comprising epidermal growth factor, chitosan, viscosity modifiers, plasticizers, and stabilizers. Specifically, the present invention relates to a sustained release film formulation for healing wound comprising epidermal growth factor as an effective ingredient and chitosan as a main base, and additionally comprising one or more antioxidants selected from the group consisting of EDTA and vitamin C; one or more viscosity modifiers selected from the group consisting of hydroxypropylmethylcellulose, gellan gum and pullulan; and one or more plasticizers selected from the group consisting of glycerin, propylene glycol, polyethylene glycol, polyvinyl alcohol and polyvinylpyrrolidone thereto. When the present film is attached to wound site, it absorbs exudation from wound site, and so is changed to hydrogel to keep wound site humid, which is good for wound-healing. And, the present film has superior attachment property to human body, and antifungal activity. Thus, the present film has more merits than simple ointment/cream formulation.

IPC Classes  ?

• A61L 27/20 - Polysaccharides

Abstract

Disclosed is a marker capable of predicting the response of AML (Acute Myeloid Leukemia) patients to anticancer therapy. Also, a kit equipped with a means for measuring the expression level of marker genes capable of predicting the response is provided for predicting the response of AML patients to anticancer drugs. Additionally, a method is provided for predicting the response of AML patients to anticancer drugs on the basis of the extent of expression of the marker genes. By applying a bio-specimen taken from AML patients to the kit to analyze the expression patterns of the genes, the response of AML patients to anticancer drugs can be predicted. The method can give information on suitable chemotherapy for AML patients, thereby improving the therapeutic effect of the anticancer drugs used and relieving the pain and economic burden of the patients.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Disclosed herein are diagnostic markers CTHRCl, CANP and KIAA0101, which are overexpressed specifically in breast or colorectal cancer. A method for diagnosing the cancer by- detecting the markers, and a method for preventing or treating by inhibiting the expression and activity of the markers are also disclosed.

IPC Classes  ?

• C12N 15/28 - Tumor necrosis factors
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to a solubilized material, and an aqueous solution and a process for preparation thereof. Particularly, the present invention relates to an ubidecarenone-containing solubilized material comprising ubidecarenone and Macrogol 15 Hydroxystearate as a solubilizer; an aqueous solution comprising a mixture of said material, and water or aqueous agent; and a process for preparing said material comprising the steps of heating 1 to 20 weight by parts of Macrogol 15 Hydroxystearate to the temperature of 50 'C or more, and forming the solubilized material by adding 1 weight by part of ubidecarenone to Macrogol 15 Hydroxystearate.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 17/18 - Antioxidants, e.g. antiradicals

Goods & Services

Cosmetics and non-medicated toiletries, namely, Nourishing Skin Creams, [ Nail enamel removers, Eyebrow pencils, Hair powder being Hair care preparations, Lavender water being perfumes made of extract of lavender, Liquid rouge, Lipsticks, Mascara,] Beauty mask pack, [ Massage gel, Massage oil, Nail polish, Enamel for manicure, Skin polishing rice bran, Nail varnish-removing preparations, Hair oil, Hair drying preparations, preparations for hair preservation and management, Hair colorants, Hair waving preparations, Color-removing preparations for hair,] Liquid foundations, Non-medicated bath preparations for addition to cosmetic baths, [ Badian essence being Star anise in the nature of oily moisturizer for after- shower use, Anti-perspirants, ] Vanishing creams, [ Bath oil, Bath powder, White make-up powder, Bay rums, Baby oil, Baby powder, Cheek colors being blush, Blushers, Perfumed powder, Dandruff lotions not for medical treatment, Dandruff creams not for medical treatment, Bath salts not for medical purposes, Aromatherapy cosmetic body care preparations other than for medical purposes, Tanning sun milk, ] Sunscreen lotions, Sunscreen creams, [ Tanning sun oils, Sun-tanning preparations, Shaving creams, Nail polishing powder, Nail colorants, Nail decolorants,] Skin milk lotions, Skin fresheners, [ essential oils of Citron, Eyeliners, Eye make-up removers, Eye shadow, ] After shave lotions, [ Eau de cologne being cologne water, Deodorants for personal use, ]Common lotions for face and body care, [ Non-medicated lip care preparations being lip brighteners, ] Non-medicated lip care preparations being lip Neutralizers, Non-medicated lip care preparations being lip conditioners, Non-medicated protective preparations for lips, [ Hair creams, Cosmetic preparations for slimming purposes, ] Cold creams, [ Cold waving solutions, Solid powder for compacts, Moustache wax,] Cleansing cream, [ Depilatory wax, Depilatory preparations, Beard dyes, Permanent wave preparations, Neutralizing preparations for permanent wave, Foundation creams, Permanent waving lotions, Face powder, ] Skin whitening creams, Hand creams, [ Perfumes, ] Balms being body balm, [ after shave balm and lip balm, Hair gel, Hair glaze, Hair dressing preparations, Hair lacquers, Hair lotions, Hair moisturizer, Hair mousse, Hair spray, Hair conditioners, Hair creams, ] Hair tonic, [ Make-up powder, Hydrogen peroxide for use on the hair, Greases for cosmetic purposes, Petroleum jelly for cosmetic purposes, Astringents for cosmetic purposes, Cosmetic pencils, Hair dyes, Bath salts, Cleansing milk for toilet purposes, Talcum powder for toilet use, Pomades for cosmetic purposes, ] Cosmetic moisture cream; [ Perfumery and fragrances for personal use, namely, Gaultheria oil used for fragrance, potpourri perfumes, safrole for use as a fragrance, ethereal essential oils, heliotropine, Lavender oil, Vanilla perfumery, Bergamot oil, Ambergris, Ionone perfumery, Jasmine oil, Rose oil, Clove oil used for fragrance, Geraniol, Compound perfumery, Mint for perfumery, Musk, Elecampane for fragrance, Incense sticks; and Soaps and detergents, namely, Soap powder, Detergents prepared from petroleum for household cleaning use, Industrial soaps,] Dry-cleaning liquid soap preparations, [ Scrubbing soap powder, Shaving soap, ] Bath soaps, Liquid soaps, Cosmetic soaps, Soap for foot perspiration, [ Deodorant soap, Drain cleaning detergent preparations for cleaning blocked drains,] Shampoos, [ Laundry soap for brightening colors in clothing, Non-medicated soaps for use as a non-medicated douche, Oils for cleaning purposes, Cleansers for detergent purposes for household use, Laundry soaps, Disinfectant soap, Almond soap,] Medicated soap, [ Glass cleaning preparations, Rinse for clothing being laundry detergent, Windscreen cleaning liquids, Paper based soaps for personal use,] Cream soaps, [ Toilet bowl detergents, Hair rinses being shampoos and Cosmetic soaps ]